Hybridon Announces Issuance of a Dominant Second Generation Ribozyme Patent

Apr 24, 2001, 01:00 ET from Hybridon

    CAMBRIDGE, Mass., April 24 /PRNewswire Interactive News Release/ --
 Hybridon (OTC Bulletin Board:   HYBN) announced today the issuance of a U.S.
 patent that contains broad claims covering ribozymes with 2'-O-methyl
 modifications. Ribozymes claimed in this patent are currently under
 preclinical and clinical evaluations by other companies for treatment of
 cancer and viral diseases. These ribozymes are also broadly used for gene
 target validation and functional genomics.
     "This important patent is the outcome of pioneering work by Hybridon
 scientists in modifying ribozymes to improve their properties as drugs and in
 other applications," said Dr. James B. Wyngaarden, Chairman of Hybridon. "We
 are pleased that Hybridon's investment in DNA chemistry over the last decade
 has resulted in the issuance of another key patent, which provides significant
 new commercial opportunities for the company, and further adds to our patent
 estate."
     U.S. Patent No. 6,204,027, "Ribozymes Having 2'-O-substituted Nucleotides
 in the Flanking Sequences," owned by the University of Massachusetts and
 exclusively licensed to Hybridon, contains claims covering hammerhead and
 hairpin ribozymes comprising one or more 2'-O-methyl-substituted nucleotides
 in one or both of the ribozyme's flanking regions.
     Located in Cambridge, MA, Hybridon, Inc. is engaged in the discovery and
 development of novel genetic medicines based primarily on antisense technology
 for the treatment of diseases for which there are currently limited or no
 effective treatments. Antisense technology involves the use of synthetic
 segments of DNA to inhibit the production of disease-associated proteins by
 interacting at the genetic level with target strands of messenger RNA.
     Hybridon owns or has exclusively licensed patents covering antisense
 chemistries, therapeutic targets and methods of oligonucleotide
 administration. Hybridon's DNA chemistry program has identified 'cyclicons', a
 novel antisense structure that simplifies the application of antisense to
 identify gene function.  Hybridon has also designed a portfolio of novel, CpG
 oligonucleotides that act as immunostimulatory agents, for use with vaccines
 or by themselves, to enhance the body's immune response.
     Hybridon's lead compound, the antisense oligonucleotide GEM(R)231, is
 currently in Phase II clinical trials for the treatment of solid tumors.
 Hybridon also has two spinouts, MethylGene, Inc. and OriGenix Technologies
 Inc., in which it holds minority ownership positions.  Hybridon has recently
 arranged for the sale of its shares in MethylGene.   For more detailed
 information about Hybridon, please visit the website at
 http://www.hybridon.com.
 
     The statements made in this press release contain certain forward-looking
 statements that involve a number of risks and uncertainties, including the
 risks that the results obtained in preclinical studies may not be indicative
 of results obtained in future studies or in clinical trials. It also includes
 the risk that Hybridon's antisense drugs may be ineffective or may not receive
 required regulatory approvals, or may not be profitable or that the company
 will be forced to cease operations due to the lack of sufficient funding. Such
 statements are only predictions and actual events or results may differ
 materially.  In addition to the matters described in this press release, risk
 factors as stated from time to time in Hybridon's SEC reports, including but
 not limited to, its Annual Report on Form 10-K, may affect the results
 achieved by Hybridon.
 
     This and other Hybridon press releases can be found at
 http://www.hybridon.com and http://www.noonanrusso.com.
 
     Contact:  R. Russell Martin, M.D., Sr. Vice President, Drug Development of
 Hybridon, Inc., 617-679-5500, rmartin@hybridon.com; or Matthew Orsagh,
 Investor and Media Relations, Noonan-Russo Communications, Inc., 212-696-4455,
 ext. 357, m.orsagh@noonanrusso.com, for Hybridon, Inc.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X35247290
 
 

SOURCE Hybridon
    CAMBRIDGE, Mass., April 24 /PRNewswire Interactive News Release/ --
 Hybridon (OTC Bulletin Board:   HYBN) announced today the issuance of a U.S.
 patent that contains broad claims covering ribozymes with 2'-O-methyl
 modifications. Ribozymes claimed in this patent are currently under
 preclinical and clinical evaluations by other companies for treatment of
 cancer and viral diseases. These ribozymes are also broadly used for gene
 target validation and functional genomics.
     "This important patent is the outcome of pioneering work by Hybridon
 scientists in modifying ribozymes to improve their properties as drugs and in
 other applications," said Dr. James B. Wyngaarden, Chairman of Hybridon. "We
 are pleased that Hybridon's investment in DNA chemistry over the last decade
 has resulted in the issuance of another key patent, which provides significant
 new commercial opportunities for the company, and further adds to our patent
 estate."
     U.S. Patent No. 6,204,027, "Ribozymes Having 2'-O-substituted Nucleotides
 in the Flanking Sequences," owned by the University of Massachusetts and
 exclusively licensed to Hybridon, contains claims covering hammerhead and
 hairpin ribozymes comprising one or more 2'-O-methyl-substituted nucleotides
 in one or both of the ribozyme's flanking regions.
     Located in Cambridge, MA, Hybridon, Inc. is engaged in the discovery and
 development of novel genetic medicines based primarily on antisense technology
 for the treatment of diseases for which there are currently limited or no
 effective treatments. Antisense technology involves the use of synthetic
 segments of DNA to inhibit the production of disease-associated proteins by
 interacting at the genetic level with target strands of messenger RNA.
     Hybridon owns or has exclusively licensed patents covering antisense
 chemistries, therapeutic targets and methods of oligonucleotide
 administration. Hybridon's DNA chemistry program has identified 'cyclicons', a
 novel antisense structure that simplifies the application of antisense to
 identify gene function.  Hybridon has also designed a portfolio of novel, CpG
 oligonucleotides that act as immunostimulatory agents, for use with vaccines
 or by themselves, to enhance the body's immune response.
     Hybridon's lead compound, the antisense oligonucleotide GEM(R)231, is
 currently in Phase II clinical trials for the treatment of solid tumors.
 Hybridon also has two spinouts, MethylGene, Inc. and OriGenix Technologies
 Inc., in which it holds minority ownership positions.  Hybridon has recently
 arranged for the sale of its shares in MethylGene.   For more detailed
 information about Hybridon, please visit the website at
 http://www.hybridon.com.
 
     The statements made in this press release contain certain forward-looking
 statements that involve a number of risks and uncertainties, including the
 risks that the results obtained in preclinical studies may not be indicative
 of results obtained in future studies or in clinical trials. It also includes
 the risk that Hybridon's antisense drugs may be ineffective or may not receive
 required regulatory approvals, or may not be profitable or that the company
 will be forced to cease operations due to the lack of sufficient funding. Such
 statements are only predictions and actual events or results may differ
 materially.  In addition to the matters described in this press release, risk
 factors as stated from time to time in Hybridon's SEC reports, including but
 not limited to, its Annual Report on Form 10-K, may affect the results
 achieved by Hybridon.
 
     This and other Hybridon press releases can be found at
 http://www.hybridon.com and http://www.noonanrusso.com.
 
     Contact:  R. Russell Martin, M.D., Sr. Vice President, Drug Development of
 Hybridon, Inc., 617-679-5500, rmartin@hybridon.com; or Matthew Orsagh,
 Investor and Media Relations, Noonan-Russo Communications, Inc., 212-696-4455,
 ext. 357, m.orsagh@noonanrusso.com, for Hybridon, Inc.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X35247290
 
 SOURCE  Hybridon